HRP20201183T1 - Selektivno smanjenje antitijela koje proizvodi cistein - Google Patents

Selektivno smanjenje antitijela koje proizvodi cistein Download PDF

Info

Publication number
HRP20201183T1
HRP20201183T1 HRP20201183TT HRP20201183T HRP20201183T1 HR P20201183 T1 HRP20201183 T1 HR P20201183T1 HR P20201183T T HRP20201183T T HR P20201183TT HR P20201183 T HRP20201183 T HR P20201183T HR P20201183 T1 HRP20201183 T1 HR P20201183T1
Authority
HR
Croatia
Prior art keywords
antibody
process according
image
antibodies
agent
Prior art date
Application number
HRP20201183TT
Other languages
English (en)
Inventor
Rudy Gerardus Elisabeth Coumans
Henri Johannes Spijker
Original Assignee
Byondis B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byondis B.V. filed Critical Byondis B.V.
Publication of HRP20201183T1 publication Critical patent/HRP20201183T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Claims (15)

1. Proces selektivnog smanjenja antitijela koje proizvodi cistein sadrži reakciju antitijela koje sadrži jedan ili više proizvedenih cisteina na položajima odabranim iz teškog lanca 40, 41, 42 i 89 sistema brojanja prema Kabatu, teškog lanca 152, 153, 155, i 171 sistema brojanja prema Eu, lakog lanca 40 i 41 sistema brojanja prema Kabatu i lakog lanca 165 i 168 sistema brojanja prema Eu, sa spojem prema formuli (I), (II), (III ), (IV), (V), (VI) ili (VII) [image] [image] [image] ili njihove soli.
2. Proces prema zahtjevu 1, naznačen time što antitijelo sadrži jedan ili više proizvedenih cisteina na položajima odabranim iz teškog lanca 40, 41, 42, 152, i 153 te lakog lanca 40, 41 i 165.
3. Proces prema zahtjevu 1 ili 2, naznačen time što antitijelo sadrži jedan ili više proizvedenih cisteina na položajima odabranim iz teškog lanca 41 i 42, te lakog lanca 40 i 41.
4. Proces prema bilo kojem od zahtjeva 1 do 3, naznačen time što antitijelo sadrži jedan proizvedeni cistein u položaju teškog lanca 41.
5. Proces prema bilo kojem od zahtjeva 1 do 4, naznačen time što je spoj formule (I), (II), (III), (IV), (V), (VI) ili (VII) prisutan u količini barem jednog molarnog ekvivalenta po molarnoj količini proizvedenog cisteina.
6. Proces prema bilo kojem od zahtjeva 1 do 5, naznačen time što spoj je spoj formule (I) ili njegova sol.
7. Proces prema bilo kojem od zahtjeva 1 do 6, naznačen time što je antitijelo monospecifično antitijelo protiv jednog od ciljeva odabranih iz skupine koja se sastoji od aneksina AI, B7H4, CA6, CA9, CA15-3, CA19-9, CA125, CA242 , CCR2, CCR5, CD2, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD44, CD47, CD56, CD70, CD70, CD74, CD79, CD115, CD123, CD138, CD203c, CD303, CD333, CEA, CEACAM, CLCA-1, CLL-1, c-MET, Cripto, CTLA4, DLL3, EGFL, EGFR, EPCAM, EPh antitijela, poput EphA2 ili EPhB3, ETBR, FAP, FcRL5, FGF, FGFR3, FOLR1, GCC, GPNMB, HER2, HMW-MAA, integrin, IGF1R, L6, Lewis A poput ugljikohidrata, Lewis X, Lewis Y, LIV1, mezotelin, MUC1, MUC16, NaPi2b, Nektin-4, PSMA, PTK7, SLC44A4, STEAP-1, 5T4 (ili TPBG, trofoblast glikoprotein), TF (tkivni faktor), TF-Ag, Tag72, TNF, TROP2, VEGF i VLA; ili bispecifično antitijelo protiv kombinacije dva cilja odabrana iz navedene skupine.
8. Proces prema zahtjevu 7, naznačen time što je antitijelo odabrano iz skupine koja se sastoji od anti-CD 115 antitijela, anti-CD 123 antitijela, anti-c-MET antitijela, anti-Cripto antitijela, anti-FAP antitijela, anti-GPNMB antitijela, anti-HER2 antitijela, anti-integrin antitijela, anti-Lewis Y antitijela, anti-MUC1 antitijela, anti-MUC16 antitijela, anti-PSMA antitijela, anti-5T4 antitijela, anti-TF antitijela, anti-TF-Ag antitijela, anti-Tag72 antitijela i anti-TROP2 antitijela.
9. Proces za pripremu konjugata antitijela sadrži proces prema bilo kojem od zahtjeva 1-8.
10. Proces prema zahtjevu 9 nadalje sadrži konjugiranje terapeutskog dijela, radiofarmaceutika, fluorescentne oznake ili hidrofilnog polimera preko veznika koji se može cijepati ili koji se ne može cijepati.
11. Proces prema zahtjevu 10, naznačen time što je terapeutski dio inhibitor tubulina, protein koji inaktivira ribosome, sredstvo za vezivanje DNA manjeg utora, sredstvo koje oštećuje DNA, sredstvo za alkiliranje DNA, sredstvo za interkaliranje DNA, sredstvo za umrežavanje DNA, RNA inhibitor polimeraze, sredstvo za cijepanje DNA ili sredstvo koje poremeti sintezu proteina ili funkciju esencijalnih staničnih proteina.
12. Proces prema zahtjevu 10 ili 11, naznačen time što je terapeutski dio duokarmicin, CBI dimer, kaliheamicin, PBD, PBD dimer, majtanzinoida, tubulizin, kamptotecin, amanitin ili derivat auristatina.
13. Proces prema zahtjevu 12, naznačen time što je terapeutski dio derivat duokarmicina.
14. Proces prema bilo kojem od zahtjeva 9 do 13, naznačen time što je konjugat antitijela antitijelo-lijek prema formuli (VIII), [image] pri čemu n je 0-3, poželjno 0-1, m predstavlja prosječan DAR od 1 do 6, poželjno od 1 do 4, R1 je odabran od [image] [image] i [image] y je 1-16, i R2 je odabran od [image]
15. Proces prema zahtjevu 14, naznačen time što je konjugat antitijela-lijek prema formuli (IX) [image]
HRP20201183TT 2016-02-12 2020-07-29 Selektivno smanjenje antitijela koje proizvodi cistein HRP20201183T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16155481 2016-02-12
EP16206761 2016-12-23
EP17705364.2A EP3458100B1 (en) 2016-02-12 2017-02-13 Selective reduction of cysteine-engineered antibodies
PCT/EP2017/053157 WO2017137628A1 (en) 2016-02-12 2017-02-13 Selective reduction of cysteine-engineered antibodies

Publications (1)

Publication Number Publication Date
HRP20201183T1 true HRP20201183T1 (hr) 2021-02-05

Family

ID=58044063

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201183TT HRP20201183T1 (hr) 2016-02-12 2020-07-29 Selektivno smanjenje antitijela koje proizvodi cistein

Country Status (14)

Country Link
US (1) US10814009B2 (hr)
EP (1) EP3458100B1 (hr)
AU (1) AU2017218615B2 (hr)
CA (1) CA3026139C (hr)
CY (1) CY1124630T1 (hr)
DK (1) DK3458100T3 (hr)
ES (1) ES2818575T3 (hr)
HR (1) HRP20201183T1 (hr)
HU (1) HUE050726T2 (hr)
LT (1) LT3458100T (hr)
PL (1) PL3458100T3 (hr)
PT (1) PT3458100T (hr)
SG (1) SG11201809830WA (hr)
WO (1) WO2017137628A1 (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831976A (zh) * 2017-05-23 2020-02-21 斯索恩生物制药有限公司 用于制备抗体-药物缀合物的双重缀合方法
JP7504025B2 (ja) * 2017-08-04 2024-06-21 アムジエン・インコーポレーテツド Ｃｙｓ－ｍａｂのコンジュゲーション方法
HUE055305T2 (hu) 2017-11-24 2021-11-29 Byondis Bv Javított eljárás vc-seco linker-hatóanyag szintézisére
US20210017222A1 (en) * 2018-03-29 2021-01-21 Abbvie Inc. Selective reduction of antibodies
CN117679532A (zh) 2019-02-15 2024-03-12 上海药明合联生物技术有限公司 用于制备具有改善的同质性的抗体-药物缀合物的方法
MX2022009696A (es) 2020-02-06 2022-09-07 Byondis Bv Combinacion que contiene un conjugado de anticuerpo-farmaco que comprende derivado de duocarmicina y tiosulfato.
KR20230035332A (ko) 2020-07-06 2023-03-13 비온디스 비.브이. 항엽산제 링커-약물 및 항체-약물 접합체
AU2022254291A1 (en) 2021-04-08 2023-10-12 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
CN117794581A (zh) 2021-06-28 2024-03-29 拜奥迪斯私人有限公司 包含磷酸抗原的缀合物及其在治疗中的用途
IL313806A (en) 2021-12-30 2024-08-01 Byondis Bv Antifolate binding drugs and antidrug conjugates
WO2023222580A1 (en) 2022-05-16 2023-11-23 Byondis B.V. Novel masked antibodies
WO2024133374A1 (en) 2022-12-22 2024-06-27 Byondis B.V. Novel linker drugs comprising phosphoantigens, novel conjugates and their use in therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2006134174A2 (en) * 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Dimeric and multimeric fviia compound
ES2815678T3 (es) 2010-04-21 2021-03-30 Syntarga Bv Conjugados de análogos de CC-1065 y conectores bifuncionales
CA3211226A1 (en) 2014-02-11 2015-08-20 Seagen Inc. Selective reduction of proteins
HRP20211710T1 (hr) * 2014-05-22 2022-02-04 Byondis B.V. Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat

Also Published As

Publication number Publication date
CA3026139C (en) 2023-09-12
US10814009B2 (en) 2020-10-27
US20190388552A1 (en) 2019-12-26
CA3026139A1 (en) 2017-08-17
AU2017218615B2 (en) 2022-02-10
SG11201809830WA (en) 2018-12-28
LT3458100T (lt) 2020-08-25
HUE050726T2 (hu) 2021-01-28
PT3458100T (pt) 2020-08-05
EP3458100B1 (en) 2020-07-01
AU2017218615A1 (en) 2018-12-13
ES2818575T3 (es) 2021-04-13
CY1124630T1 (el) 2022-03-24
DK3458100T3 (da) 2020-08-03
PL3458100T3 (pl) 2020-11-30
WO2017137628A1 (en) 2017-08-17
EP3458100A1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
HRP20201183T1 (hr) Selektivno smanjenje antitijela koje proizvodi cistein
ES2966473T3 (es) Derivados de camptotecina
RU2019142720A (ru) Способ двойной конъюгации для получения конъюгатов антитело-лекарственное средство
JP2011519864A5 (hr)
JP6204294B2 (ja) 新規ベンゾジアゼピン誘導体
CN107614488B (zh) 新型亲水连接体和其在配体-药物共轭偶联物上的应用
HRP20200551T1 (hr) Axl-specifični konjugati protutijelo-lijek za liječenje raka
SI2582728T1 (en) Human Antibodies Conjugates against a Tissue Factor
JP2018523471A5 (hr)
JP2017095457A5 (hr)
RU2019113990A (ru) Нелинейные саморасщепляющиеся линкеры и их конъюгаты
JP2020075912A (ja) 細胞障害性ベンゾジアゼピン誘導体
RU2017139490A (ru) Конъюгаты лекарственных средств, содержащие антитела против клаудина 18.2
RU2017102988A (ru) Антитела против рецептора фолиевой кислоты 1, их иммуноконъюгаты и использование
RU2016141267A (ru) Антитела против egfr и конъюгаты антитело-лекарственное средство
IL278574B1 (en) Compounds acting on glycans and methods of using them
KR102681168B1 (ko) 자기희생적 펩티드 링커 및 이들의 접합체를 갖는 메이탄시노이드 유도체
RU2016117810A (ru) Конъюгаты белок-полимер-лекарственное средство
JP2020526584A5 (hr)
JP2023022328A5 (hr)
HRP20221298T1 (hr) Anti-ror2 protutijela, fragmenti protutijela, njihovi imunokonjugati i njihove uporabe
RU2016102116A (ru) Конъюгаты антител с лекарственными агентами, обладающие улучшенной стабильностью, и их применение
JP2019512262A5 (hr)
JP2021503915A5 (hr)
CA2516028A1 (en) Conjugates comprising a cancer targeting molecule linked to a liver-expressed chemokine